NCT05252546
Breast Cancer Type: HER2+
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Not yet recruiting
Phase 1
Drug Category: Tyrosine-Kinase Inhibitor

Key Eligibility Criteria:

Gender: All
Age: 18 Years to 45 Years (Adult))
Location of Metastases: Brain
Additional Notes: 
Exclusions: 
https://ClinicalTrials.gov/show/NCT05252546